Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALD1910 + sumatriptan
- Development stage
- Phase 1
- Lead developer
- Lundbeck
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Administration
- Subcutaneous (for ALD1910, As mAb), Oral, Intranasal, Subcutaneous (for Sumatriptan)
01
Overview
**ALD1910 + sumatriptan** is an investigational combination of a monoclonal antibody (ALD1910) and a small molecule triptan (sumatriptan), both designed for the treatment of migraine. ALD1910 is a high-affinity, neutralizing monoclonal antibody targeting both forms of pituitary adenylate cyclase-activating peptide (PACAP-38 and PACAP-27), thereby blocking PACAP signaling pathways implicated in migraine pathophysiology[2][4]. Sumatriptan is a selective serotonin (5-HT1B/1D) receptor agonist ("triptan") that treats acute migraine attacks by inducing vasoconstriction of intracranial blood vessels and inhibiting the release of pro-inflammatory neuropeptides[1]. This combination would theoretically provide both acute relief (via sumatriptan) and potential prevention or modulation of migraine triggers at the pathway level (via ALD1910), targeting two distinct and complementary mechanisms underlying migraine attacks.
- Other names
- sumatriptan
02
Targets
HTR1A (Serotonin receptor 1A (5-hydroxytryptamine receptor 1A))HTR1B (5-Hydroxytryptamine Receptor 1B)HTR1D (5-hydroxytryptamine receptor 1D)HTR1F (Serotonin 5-HT1F receptor)PACAP (Pituitary adenylate cyclase-activating polypeptide)
Beyond the preview
Go deeper on ALD1910 + sumatriptan.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALD1910 + sumatriptan.